Lorenzo Falchi1. 1. Division of Hematology/Oncology, New York-Presbyterian Hospital/Columbia University Medical Center, New York, NY, 10032, USA. lmf2155@cumc.columbia.edu.
Abstract
PURPOSE OF THIS REVIEW: The present review focuses on key aspects of non-Hodgkin lymphoma (NHL) evasion of immune surveillance and how these can be leveraged to devise effective immunotherapy strategies. RECENT FINDINGS: In recent years, significant progress has been made in the field of cancer immunotherapy. In particular, the remarkable clinical results of anti-programmed death (PD)-1/PD-ligand (L)1 antibodies are revolutionizing the treatment approach to multiple solid and hematologic tumors. In patients with B or T cell NHL, immune checkpoint inhibition has produced mixed results, in part owing to the high complexity of the tumor immune microenvironment. Rationally designed combinations of PD-1/PD-L1 blockers with other antibody- or cell-based immunotherapies, or small molecules are being tested in clinical trials. A clearer understanding of the relationship between host immune dysfunction and cancer development and growth, often referred to as cancer "immuno-editing," has enabled the discovery and successful clinical application of several immunotherapeutic agents, such as the immune checkpoint inhibitors (ICI).
PURPOSE OF THIS REVIEW: The present review focuses on key aspects of non-Hodgkin lymphoma (NHL) evasion of immune surveillance and how these can be leveraged to devise effective immunotherapy strategies. RECENT FINDINGS: In recent years, significant progress has been made in the field of cancer immunotherapy. In particular, the remarkable clinical results of anti-programmed death (PD)-1/PD-ligand (L)1 antibodies are revolutionizing the treatment approach to multiple solid and hematologic tumors. In patients with B or T cell NHL, immune checkpoint inhibition has produced mixed results, in part owing to the high complexity of the tumor immune microenvironment. Rationally designed combinations of PD-1/PD-L1 blockers with other antibody- or cell-based immunotherapies, or small molecules are being tested in clinical trials. A clearer understanding of the relationship between host immune dysfunction and cancer development and growth, often referred to as cancer "immuno-editing," has enabled the discovery and successful clinical application of several immunotherapeutic agents, such as the immune checkpoint inhibitors (ICI).
Authors: Katherine B Chiappinelli; Pamela L Strissel; Alexis Desrichard; Huili Li; Christine Henke; Benjamin Akman; Alexander Hein; Neal S Rote; Leslie M Cope; Alexandra Snyder; Vladimir Makarov; Sadna Budhu; Sadna Buhu; Dennis J Slamon; Jedd D Wolchok; Drew M Pardoll; Matthias W Beckmann; Cynthia A Zahnow; Taha Merghoub; Taha Mergoub; Timothy A Chan; Stephen B Baylin; Reiner Strick Journal: Cell Date: 2015-08-27 Impact factor: 41.582
Authors: David A Wada; Ryan A Wilcox; Susan M Harrington; Eugene D Kwon; Stephen M Ansell; Nneka I Comfere Journal: Am J Hematol Date: 2011-02-15 Impact factor: 10.047
Authors: Michael R Green; Stefano Monti; Scott J Rodig; Przemyslaw Juszczynski; Treeve Currie; Evan O'Donnell; Bjoern Chapuy; Kunihiko Takeyama; Donna Neuberg; Todd R Golub; Jeffery L Kutok; Margaret A Shipp Journal: Blood Date: 2010-07-13 Impact factor: 22.113
Authors: Matthew S Davids; Haesook T Kim; Pavan Bachireddy; Caitlin Costello; Rebecca Liguori; Alexandra Savell; Alexander P Lukez; David Avigan; Yi-Bin Chen; Peter McSweeney; Nicole R LeBoeuf; Michael S Rooney; Michaela Bowden; Chensheng W Zhou; Scott R Granter; Jason L Hornick; Scott J Rodig; Masahiro Hirakawa; Mariano Severgnini; F Stephen Hodi; Catherine J Wu; Vincent T Ho; Corey Cutler; John Koreth; Edwin P Alyea; Joseph H Antin; Philippe Armand; Howard Streicher; Edward D Ball; Jerome Ritz; Asad Bashey; Robert J Soiffer Journal: N Engl J Med Date: 2016-07-14 Impact factor: 91.245
Authors: D Rossille; I Azzaoui; A L Feldman; M J Maurer; G Labouré; M Parrens; C Pangault; T M Habermann; S M Ansell; B K Link; K Tarte; T E Witzig; T Lamy; S L Slager; M Roussel; N Milpied; J R Cerhan; T Fest Journal: Leukemia Date: 2017-01-27 Impact factor: 11.528
Authors: Kerry J Savage; Stefano Monti; Jeffery L Kutok; Giorgio Cattoretti; Donna Neuberg; Laurence De Leval; Paul Kurtin; Paola Dal Cin; Christine Ladd; Friedrich Feuerhake; Ricardo C T Aguiar; Sigui Li; Gilles Salles; Francoise Berger; Wen Jing; Geraldine S Pinkus; Thomas Habermann; Riccardo Dalla-Favera; Nancy Lee Harris; Jon C Aster; Todd R Golub; Margaret A Shipp Journal: Blood Date: 2003-08-21 Impact factor: 22.113
Authors: P S Linsley; P M Wallace; J Johnson; M G Gibson; J L Greene; J A Ledbetter; C Singh; M A Tepper Journal: Science Date: 1992-08-07 Impact factor: 47.728
Authors: Tomoko Freshwater; Anna Kondic; Malidi Ahamadi; Claire H Li; Rik de Greef; Dinesh de Alwis; Julie A Stone Journal: J Immunother Cancer Date: 2017-05-16 Impact factor: 13.751